Opinion|Videos|November 18, 2025
Additional Data with HER2-Targeted Agents in Metastatic Breast Cancer
Panelists discuss how newer HER2-targeted therapies show promise for CNS disease control and broader metastatic management.
Advertisement
Episodes in this series
Panelists discuss how:
HER2-low metastatic breast cancer represents a rapidly advancing treatment area, with novel ADCsantibody-drug conjugates driving paradigm shifts. The conversation centers on how these agents—by leveraging potent payload delivery—offer survival benefits previously unseen in this population. They examine HER3-directed therapies as an emerging frontier, considering their mechanistic rationale and early clinical trial outcomes. The experts discuss the expanding biomarker continuum that is blurring traditional HER2 categories and enabling personalized therapy strategies.
Advertisement
Related to this article
Andrew Kuykendall, MD, discusses the FDA approval of rusfertide and how to apply it in clinical practice for polycythemia vera management.
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
The NMPA has approved of pirtobrutinib in treatment-naive and previously treated CLL/SLL.
Roswell Park Comprehensive Cancer Center recognized members of its clinical, research and healthcare teams during the second annual Excellence Awards.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
China's NMPA Approves Pirtobrutinib Across CLL
3
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
4
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
5